{"id":859372,"date":"2025-06-11T06:55:29","date_gmt":"2025-06-11T10:55:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/"},"modified":"2025-06-11T06:55:29","modified_gmt":"2025-06-11T10:55:29","slug":"nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/","title":{"rendered":"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery"},"content":{"rendered":"<h2>\nLeading Global Pharma Joins Danish Enterprises, Startups and Public Health Systems Using AI Factories to Improve Drug Discovery and Healthcare<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">PARIS, June  11, 2025  (GLOBE NEWSWIRE) &#8212; <strong>NVIDIA GTC Paris at VivaTech <\/strong>\u2014<strong>\u00a0<\/strong>NVIDIA today announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. The work supports Novo Nordisk\u2019s agreement with <a href=\"https:\/\/novonordiskfonden.dk\/en\/projects\/danish-centre-for-ai-innovation\/\" rel=\"nofollow\" target=\"_blank\">DCAI<\/a> to use the Gefion sovereign AI supercomputer.<\/p>\n<p align=\"left\">The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development and to apply advanced simulation and <a href=\"https:\/\/www.nvidia.com\/en-us\/glossary\/generative-physical-ai\/\" rel=\"nofollow\" target=\"_blank\">physical AI<\/a> technologies.<\/p>\n<p align=\"left\">\u201cAI is essential for every industry, and there\u2019s no other field that will benefit more from acceleration than drug discovery,\u201d said Rory Kelleher, senior director of business development for life sciences at NVIDIA. \u201cWorking with Novo Nordisk, we\u2019re advancing critical R&amp;D applications with fundamental tools that can harness the full potential of generative and agentic AI to improve pharmaceutical development.\u201d<\/p>\n<p align=\"left\">\n        <strong>Novo Nordisk Taps Advanced AI to Accelerate Innovation<\/strong><br \/>\n        <br \/>DCAI\u2019s Gefion supercomputer, powered by <a href=\"https:\/\/www.nvidia.com\/en-us\/data-center\/dgx-superpod\/\" rel=\"nofollow\" target=\"_blank\">NVIDIA DGX SuperPOD<\/a>\u2122, provides Novo Nordisk an <a href=\"https:\/\/www.nvidia.com\/en-us\/glossary\/ai-factory\/\" rel=\"nofollow\" target=\"_blank\">AI factory<\/a> for running drug discovery and agentic AI workloads. Novo Nordisk will use <a href=\"https:\/\/www.nvidia.com\/en-us\/clara\/biopharma\/\" rel=\"nofollow\" target=\"_blank\">NVIDIA BioNeMo<\/a>\u2122 for generative AI-powered drug discovery, <a href=\"https:\/\/www.nvidia.com\/en-us\/ai-data-science\/products\/nim-microservices\/\" rel=\"nofollow\" target=\"_blank\">NVIDIA NIM<\/a>\u2122 and <a href=\"https:\/\/www.nvidia.com\/en-us\/ai-data-science\/products\/nemo\/\" rel=\"nofollow\" target=\"_blank\">NVIDIA NeMo<\/a>\u2122 microservices for building customized agentic workflows, and the <a href=\"https:\/\/www.nvidia.com\/en-us\/omniverse\/\" rel=\"nofollow\" target=\"_blank\">NVIDIA Omniverse<\/a>\u2122 platform to create physically accurate simulation environments for developing physical AI applications.<\/p>\n<p align=\"left\">Novo Nordisk researchers will focus on several AI research programs, including using single-cell models to predict cellular responses to drug candidates and structures, as well as designing models to build molecules with drug-like properties. The companies will also collaborate on tapping Novo Nordisk\u2019s vast global scientific literature to build biomedical large language models, enabling researchers to uncover correlations between genes, proteins and diseases.<\/p>\n<p align=\"left\">\u201cBy coupling NVIDIA\u2019s accelerated computing platform and expertise with Novo\u2019s deep expertise in life sciences research and development, we aim to build custom models that will aid our scientists in developing new medicines faster and more efficiently,\u201d said Mishal Patel, senior vice president, AI and digital innovation at Novo Nordisk. \u201cGefion will allow us to run experiments at an unprecedented scale.\u201d<\/p>\n<p align=\"left\">\n        <strong>Advancing Denmark\u2019s Healthcare Ecosystem<\/strong><br \/>\n        <br \/>DCAI owns and operates Gefion, Denmark\u2019s flagship AI supercomputer. DCAI is helping lower the barrier for accessing advanced computing capabilities and enabling companies in Denmark to pursue research and development across healthcare and drug discovery.<\/p>\n<p align=\"left\">\u201cWith Gefion\u2019s computational power, we can tackle the toughest R&amp;D challenges, with the ultimate goal of unlocking new possibilities for pharmaceutical research and development,\u201d said Nadia Carlsten, CEO of DCAI. \u201cBy combining Gefion\u2019s capabilities with NVIDIA\u2019s expertise, our customers can accelerate innovation even further.\u201d<\/p>\n<p align=\"left\">Gefion has already been used by multiple customers to advance healthcare and drug discovery.<\/p>\n<p align=\"left\">Teton, a Danish startup and member of the <a href=\"https:\/\/www.nvidia.com\/en-us\/startups\/\" rel=\"nofollow\" target=\"_blank\">NVIDIA Inception<\/a> program for cutting-edge startups, is tapping into Gefion to accelerate the development of its AI care companion for hospitals, using cameras and sensors installed in patient rooms to create real-time 3D <a href=\"https:\/\/www.nvidia.com\/en-us\/glossary\/digital-twin\/\" rel=\"nofollow\" target=\"_blank\">digital twins<\/a>. This allows nurses to monitor patients remotely and receive alerts about potential health issues. Teton\u2019s technology aims to reduce workload burden on nurses \u2014 freeing them up for higher-value tasks \u2014 and improve patient care, with early trials showing up to a 25% reduction in nightshift duties.<\/p>\n<p align=\"left\">Last month, DCAI announced that one of the first pharma companies to use Gefion will tap the supercomputer to accelerate drug discovery and development in neurological and psychiatric disorders. Another venture-backed company is using Gefion to accelerate the development of oral alternatives to widely used biologics and to target proteins that are currently difficult or impossible to drug with available compounds.<\/p>\n<p align=\"left\">Gefion will also be used as part of an effort by Danish health organizations to unite previously siloed health data into a single national analysis platform, which will provide researchers with secure access to interconnected health data. Along with supercomputing resources, this will make it easier to analyze large datasets, identify disease patterns earlier and develop more personalized treatments.<\/p>\n<p align=\"left\">Watch the <a href=\"https:\/\/www.nvidia.com\/en-eu\/gtc\/keynote\/\" rel=\"nofollow\" target=\"_blank\">NVIDIA GTC Paris keynote<\/a> from NVIDIA founder and CEO Jensen Huang at VivaTech, and explore <a href=\"https:\/\/www.nvidia.com\/en-eu\/gtc\/session-catalog\/?tab.allsessions=1700692987788001F1cG#\/\" rel=\"nofollow\" target=\"_blank\">GTC Paris sessions<\/a>.<\/p>\n<p align=\"left\">\n        <strong>About NVIDIA<br \/><\/strong><br \/>\n        <a href=\"https:\/\/www.nvidia.com\/\" rel=\"nofollow\" target=\"_blank\">NVIDIA<\/a> (NASDAQ: NVDA) is the world leader in accelerated computing.<\/p>\n<p align=\"left\">\n        <strong>For further information, contact:<\/strong><br \/>\n        <br \/>Janette Ciborowski<br \/>Enterprise Communications<br \/>NVIDIA Corporation<br \/>+1-734-330-8817<br \/><a href=\"mailto:jciborowski@nvidia.com\" rel=\"nofollow\" target=\"_blank\">jciborowski@nvidia.com<\/a><\/p>\n<p align=\"left\">Certain statements in this press release including, but not limited to, statements as to: working with Novo Nordisk, NVIDIA advancing critical R&amp;D applications with fundamental tools that can harness the full potential of generative and agentic AI to improve pharmaceutical development; the benefits, impact, performance, and availability of NVIDIA\u2019s products, services, and technologies; expectations with respect to NVIDIA\u2019s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the \u201csafe harbor\u201d created by those sections based on management\u2019s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA\u2019s reliance on third parties to manufacture, assemble, package and test NVIDIA\u2019s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA\u2019s existing product and technologies; market acceptance of NVIDIA\u2019s products or NVIDIA\u2019s partners\u2019 products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA\u2019s products or technologies when integrated into systems; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company\u2019s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.<\/p>\n<p align=\"left\">\u00a9 2025 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, NVIDIA BioNeMo, NVIDIA DGX SuperPOD, NVIDIA NeMo, NVIDIA NIM and NVIDIA Omniverse are trademarks and\/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.<\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/92c0c3db-28ea-43c7-b0d5-9ac3b350edaf\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/92c0c3db-28ea-43c7-b0d5-9ac3b350edaf<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTg0ZWExNjctODE2YS00OTRlLTljMDYtZWRhNGIxNmMxNTdjLTEwMTg0ODUtMjAyNS0wNi0xMS1lbg==\/tiny\/NVIDIA-CORPORATION.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Leading Global Pharma Joins Danish Enterprises, Startups and Public Health Systems Using AI Factories to Improve Drug Discovery and Healthcare PARIS, June 11, 2025 (GLOBE NEWSWIRE) &#8212; NVIDIA GTC Paris at VivaTech \u2014\u00a0NVIDIA today announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. The work supports Novo Nordisk\u2019s agreement with DCAI to use the Gefion sovereign AI supercomputer. The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development and to apply advanced simulation and physical AI technologies. \u201cAI is essential for every industry, and there\u2019s no other field that will benefit more from acceleration than drug discovery,\u201d said Rory Kelleher, senior director &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-859372","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Leading Global Pharma Joins Danish Enterprises, Startups and Public Health Systems Using AI Factories to Improve Drug Discovery and Healthcare PARIS, June 11, 2025 (GLOBE NEWSWIRE) &#8212; NVIDIA GTC Paris at VivaTech \u2014\u00a0NVIDIA today announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. The work supports Novo Nordisk\u2019s agreement with DCAI to use the Gefion sovereign AI supercomputer. The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development and to apply advanced simulation and physical AI technologies. \u201cAI is essential for every industry, and there\u2019s no other field that will benefit more from acceleration than drug discovery,\u201d said Rory Kelleher, senior director &hellip; Continue reading &quot;NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-11T10:55:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery\",\"datePublished\":\"2025-06-11T10:55:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/\"},\"wordCount\":1170,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/\",\"name\":\"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI=\",\"datePublished\":\"2025-06-11T10:55:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/","og_locale":"en_US","og_type":"article","og_title":"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery - Market Newsdesk","og_description":"Leading Global Pharma Joins Danish Enterprises, Startups and Public Health Systems Using AI Factories to Improve Drug Discovery and Healthcare PARIS, June 11, 2025 (GLOBE NEWSWIRE) &#8212; NVIDIA GTC Paris at VivaTech \u2014\u00a0NVIDIA today announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. The work supports Novo Nordisk\u2019s agreement with DCAI to use the Gefion sovereign AI supercomputer. The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development and to apply advanced simulation and physical AI technologies. \u201cAI is essential for every industry, and there\u2019s no other field that will benefit more from acceleration than drug discovery,\u201d said Rory Kelleher, senior director &hellip; Continue reading \"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-11T10:55:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery","datePublished":"2025-06-11T10:55:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/"},"wordCount":1170,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/","name":"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI=","datePublished":"2025-06-11T10:55:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjkxOSM2OTg0ODczIzIwMDY5MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859372","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=859372"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859372\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=859372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=859372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=859372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}